

JILL T. JOHNSON, PHARM.D., BCPS

December 2025

Work Address:

University of Arkansas for Medical Sciences (UAMS)
College of Pharmacy, #522-4
4301 W. Markham Street
Little Rock, Arkansas 72205

Phone: 501-686-7919
Email: johnsonjillt@uams.edu

EDUCATION AND TRAINING

Doctor of Pharmacy Degree: May 1993

UAMS College of Pharmacy, Little Rock, Arkansas

ASHP-Accredited Residency Training: July 1993 to June 1994

Pharmacy Practice Residency, Veterans Affairs Medical Center, Little Rock, Arkansas

Pre-Pharmacy Education: August 1986 to May 1989

University of Arkansas, Fayetteville, Arkansas

PROFESSIONAL BOARD CERTIFICATION

NABP Pharmacist Licensure: Arkansas, since 1993

Board Certification in Pharmacotherapy Specialty (BCPS), 1997-present

Immunizations Administration Certification, since 2020

Arkansas Collaborative Practice Certification

CURRENT PROFESSIONAL EXPERIENCE

July 2015-Present	Professor with Tenure, Department of Pharmacy Practice, UAMS, Little Rock, AR
July 1994 - Present	Interdisciplinary Internal Medicine Team 3A Member, University Hospital, UAMS, Little Rock, AR Vancomycin, Aminoglycoside, Warfarin, & TPN Monitoring Service
May 2016-Present	Committee Member, Institute for Clinical and Economic Review (ICER) Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), Chair 2024-2026
January 2024-Present	Chair, Targeted Drug Review Subcommittee to the P&T Committee, Formulary Management
June 1999 - Present	Voting Member, UAMS Hospital Pharmacy & Therapeutics Committee, Formulary Management
January 2004-Present	Clinical Consultant, Evidence-based Prescription Drug Program, UAMS College of Pharmacy
January 2004 - Present	Clinical Consultant, Arkansas State Employees/Public School Employees, Employee Benefits Division, Formulary Management for Prescription Drug Program
July 2004 - Present	Committee Member, University of Arkansas Systems Pharmacy Advisory Committee
January 2017-Present	Clinical Pharmacy Consulting, Jill Johnson Consulting LLC, Established January 2017
August 2005 - Present	Expert Witness Cases. Various pharmaceutical-related cases
January 2007-June 2023	Board Member, AR Medicaid Drug Utilization Review Board (DUR Board)

CURRENT TEACHING

1994-Present	<u>PhPr 6714 Clerkship in General Internal Medicine</u> Preceptor, Responsibilities: Rounding with Multidisciplinary General Internal Medicine Team, 2-fourth year pharmacy students per month, 5 months per year
2011-Present	<u>PhPr 7303 Evidence-Based Medicine, Biostatistics, Pharmacoeconomics</u> <u>Medical Literature Critical Appraisal</u> Course Coordinator & Lecturer (Fall 2008-Present) Lectures: Introduction to Evidence-based Medicine, EBM Framework/Asking Clinical Questions, Validity of Clinical Trials: Populations, External validity, Exclusion/Inclusion, Study Design: Controlled Trials, Randomization, Allocation Concealment, Blinding, Loss to Follow-up, Trial Results: Analysis by Intention to Treat vs Per Protocol Analysis, Factoring in Baseline Characteristics, Composite endpoints, Flawed Assumptions, Run-ins, Calculating Relative Risks, Number Needed to Treat/Harm; Interpreting Hazard Ratios, Odds Ratios, and 95% Confidence Intervals, Levels of Evidence, Statistical vs Clinical Significance, Practice Guidelines
2016-Present	<u>Special Problems Elective in EBM</u> Third-year Pharm.D. Students each semester
2019-Present	<u>PhPr 7306 Pharmacy Management</u> Third-year Pharm.D. Students Managed Care; Pharmaceutical Promotions
2022-Present	<u>PhPr 71143 001 Social and Administrative Sciences I</u> , new curriculum 2025 Fall Managed Care Pharmacy, PBMs
2010-Present	<u>PhPr 7103 Career Orientation</u> First-year Pharm.D. Students
1995- Present	<u>PhSc 7205 Clinical Pharmacokinetics</u> Heparin, Low Molecular Weight Heparins, DOACs, and Warfarin

PEER-REVIEWED PUBLICATIONS since 2010

Book contributions, Invited Content:

- 1. Johnson JT.** Evaluating Clinical Literature: An Overview. In: Aparasu RR, Bentley JP, eds. *Principles of Research Design and Drug Literature Evaluation*. 2nd Ed. NY, NY: McGraw Hill; 9/2019: Online Access Pharmacy, Chapter 17. <https://accesspharmacy.mhmedical.com/book.aspx?bookid=2733>
- 2. Johnson JT.** Evaluating Clinical Literature: An Overview. In: Aparasu RR, Bentley JP, eds. *Principles of Research Design and Drug Literature Evaluation*. 1st Ed. Burlington, MA: Jones & Bartlett Learning; 2014: 274-288.
- 3. Johnson JT.** Clinical Scenario and Clinical Significance: Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission. Glennon RA, Dukat M. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Seventh Ed*. Philadelphia: Lippincott Williams & Wilkins; 2013: 366, 367, 392-3.
- 4. Johnson JT.** Clinical Scenario and Clinical Significance: Central Analgesics. Williams DA, Roche VF, Roche EB. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Seventh Ed*. Philadelphia: Lippincott Williams & Wilkins; 2013: 659, 694.
- 5. Johnson JT.** Clinical Scenario and Clinical Significance: Nonsteroidal Anti-Inflammatory Drugs. Borne R, Levi M, Wilson N. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Seventh Ed*. Philadelphia: Lippincott Williams & Wilkins; 2013: 987, 990, 1040-41.

Journal articles:

1. Golden, William, Cheng Peng, E. J. Shoptaw, Jacob Painter, Ryan Dare, Jeremy Thomas, Holly Maples, Benjamin Teeter, and **Jill Johnson**. "Measurement of Practice-Level Antibiotic Utilization in a Medicaid Patient-Centered Medical Home Program." *The Annals of Family Medicine* 23, no. 5 (2025): 407-411.
2. **Johnson J**. Recurrent shingles vaccine-induced neuropathy upon rechallenge. *Clinical Case Reports*. Submitted 2024.
3. **Johnson J**, DeYoung O, Keisner S. Covering pitolisant instead of oxybate salts for cataplexy. *American Journal of Managed Care*. Submitted 2023.
4. King J, McAdam-Marx C, McCaleb R, Davis D, Bemberg GB, **Johnson JT**. "Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan." *Journal of managed care & specialty pharmacy* 25.6 (2019): 646-651.
5. McCaleb, Rachael V., and **Jill T. Johnson**. "Severe, prolonged, denosumab-induced hypocalcemia with recovery after 111 days of high dose calcium supplementation: a case report." *AACE Clinical Case Reports* (2019). <https://doi.org/10.4158/ACCR-2018-0295>
6. McAdam-Marx C, Li C, Hu B, Hight K, **Johnson J**. Trends in insulin costs and adherence in commercially insured patients with diabetes: 2007-2014. *J Manag Care Pharm*. 2018. (Submitted, voluntarily unsubmitted)
7. Shewale AR, **Johnson JT**, Li C, Nelsen D, Martin BC. Net clinical benefits of guidelines and decision tool recommendations for oral anticoagulant use among patients with atrial fibrillation. *J Stroke Cerebrovascular Dis*. 2015;24(12).
8. Shewale A, **Johnson J**, Li C, Nelsen D, Martin B. Variation in anticoagulant recommendations by the guidelines and decision tools among patients with atrial fibrillation. *Healthcare*. 2015;3(1):130-145.
9. Dayer LE, Hutchins LF, **Johnson JT**. Treatment of metastatic melanoma with pazopanib: a report of five patient cases. *Journal of Oncology Pharmacy Practice*. 2014. Online first: <http://opp.sagepub.com/content/early/2014/02/27/1078155214524084>
10. Kaye CJ, Neill KK, Davis D, **Johnson JT**. Statin Cost and Utilization Outcomes after Implementation of Reference-based Pricing. *Am J Pharm Benefits*. 2013;5(1):e8-e14.
11. Neill KK, **Johnson JT**. An Advanced Pharmacy Practice Experience in Application of Evidence-based Policy. *American Journal of Pharmaceutical Education*. 2012;76(7) article 133.
12. **Johnson JT**, Neill, KK, Davis D. Five-Year Examination of Utilization and Drug Cost Outcomes Associated with Benefit Design Changes Including Reference Pricing for Proton Pump Inhibitors in a State Employee Health Plan. *J Manag Care Pharm*. 2011;17(3):200-12. April 2011. *nominated for the JMCP Award for Excellence, 2011.

PRESENTATIONS (since year 2010)

INTERNATIONAL

- Poster Presentation: Shewale AR, Nelsen DA, **Johnson JT**, Li C, Martin B. Comparison of the guidelines and decision tool recommendations for oral anticoagulant use among patients with atrial fibrillation. University of Arkansas for Medical Sciences, AR, USA. Accepted to ISPOR 19th Annual International Meeting. May 31 - June 4, 2014, at Palais des Congrès de Montréal, Montreal, QC, Canada.
- Poster Presentation: Shewale AR, Nelsen DA, **Johnson JT**, Li C, Martin B. Comparison of decision support tools and guidelines used to guide anticoagulation therapy for patients with nonvalvular atrial fibrillation. University of Arkansas for Medical Sciences, AR, USA. Accepted to ISPOR 19th Annual International Meeting. May 31 - June 4, 2014, at Palais des Congrès de Montréal, Montreal, QC, Canada.
- Poster Presentation: Potukuchi PK, **Johnson JT**, Martin B, Hutchison LC, Bursac Z, Said Q. Treatment

patterns of urinary incontinence in the presence of comorbidities. University of Arkansas for Medical Sciences, AR, USA. Accepted to ISPOR 19th Annual International Meeting. May 31 - June 4, 2014, at Palais des Congrès de Montréal, Montreal, QC, Canada.

- Poster Presentation: Potukuchi PK, **Johnson JT**, Martin B, Hutchison LC, Bursac Z, Said Q. Impact of arthritis and other comorbidities on incidence of urinary incontinence: a case control study. University of Arkansas for Medical Sciences, AR, USA. Accepted to ISPOR 19th Annual International Meeting. May 31 - June 4, 2014, at Palais des Congrès de Montréal, Montreal, QC, Canada.

NATIONAL

- Poster Presentation: Hsu E, **Johnson J**. Rationale for coverage of atidarsagene autotemcel (Lenmeldy) for metachromatic leukodystrophy. 2024. Presented at Academy of Managed Care Pharmacy (AMCP Nexus), Las Vegas, NV.
- Poster Presentation: **Johnson J**, Peng C, Dare R, Painter J, Maples H, Thomas J, Teeter B, Shoptaw E, Golden W. Antibiotic Prescribing Changes in Adults During COVID-19 in Outpatient Patient-Centered Medical Homes (PCMH) in Arkansas. 2022. Presented at IDWeek 2022, Washington DC.
- Poster Presentation: Byrd K, Bailey B, **Johnson J**, DeYoung O, Hutchison L. Development and Implementation of a PGY2 Population Health Management and Data Analytics Pharmacy Residency Program. 2022. Presented at ASHP Midyear.
- Poster Presentation: Thomas J, Peng C, **Johnson J**, Maples H, Teeter B, Painter J, Dare R, Shoptaw E, Golden W. Impact of COVID on Antibiotic Prescribing Patterns in a Medicaid Population. 2022 ACCP Abstract #59634. Virtual Poster Presentation.
- Poster Presentation: Maples H, Peng C, Painter J, Dare R, **Johnson J**, Thomas J, Shoptaw E, Golden W. The Impact of Covid-19 on Pediatric Antimicrobial Prescribing in Primary Care Medical Homes in Arkansas. 2022. Pediatric Antimicrobial Stewardship Annual Meeting, St.Louis, MO.
- Poster Presentation: McAdam-Marx C, Li C, **Johnson J**. Trends in insulin cost share and utilization in commercially insured patients with diabetes: 2007-2014. AMCP Nexus Meeting, Orlando, FL, 10/2018.
- Poster Presentation: King J, McAdam-Marx C, Davis D, Bemberg GB, **Johnson JT**. Cost and utilization outcomes after exclusion of dipeptidyl peptidase-4 (DPP-4) inhibitors in a self-funded managed care plan. ACCP Virtual Poster Presentation. 2017.
- Poster Presentation: Mullings A, **Johnson JT**. Cost and Utilization Outcomes of Antivirals Used in the Treatment of Herpes Labialis After Exclusion of Topical Antivirals in a Self-Funded Managed Care Plan. AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA, April 20, 2016.
- Poster Presentation: Shewale AR, Nelsen DA, **Johnson JT**, Li C, Martin BC. Net clinical benefit of the 2014 AHA/ACC/HRS Guideline used to guide anticoagulation therapy for patients with nonvalvular atrial fibrillation. Southern Pharmacy Administration Conference (SpAC) Oklahoma City, OK, June 20-22, 2014.
- Poster Presentation: Dayer LE, Merrell KS, **Johnson JT**, Hutchins LF. Treatment of metastatic melanoma with pazopanib: a report of 5 patient cases. Presented at American Society of Health-Systems Pharmacists (ASHP) Midyear Clinical Meeting, Orlando, FL, December 8-12, 2013. (Poster #1-039)
- Poster Presentation: Kaye C, Davis DA, Neill KK, **Johnson J**. Statin Cost & Utilization Outcomes After Implementation of Reference-based Pricing. Presented at the 24th Annual Academy of Managed Care Pharmacy Meeting, San Francisco, CA. April 2012.
- Poster Presentation: Neill K, Warmack S, **Johnson J**, Gubbins P, Schneider E, Carle M. Implementation of a Faculty Item Review Process for Examination Content in the Therapeutics Coursework. Presented at the Annual Meeting of the American Association of Colleges of Pharmacy, Seattle, WA. July 2010; AJPE 2010;74(5) Article 96.

STATE

- **Johnson J.** Alzheimer's Disease & Dementia Advisory Council. Invited discussion. Rep. Julie Mayberry. 9/26/23. State Capitol, Little Rock, AR.
- Davis J, **Johnson J.** Rationale for noncoverage of beremagene geperpavec for dystrophic epidermolysis bullosa. 2023. 2nd Place Poster, AAHP, Little Rock.
- Quattlebaum B, **Johnson J.** Development of evidence-based prior authorization criteria for Etranacogene dezaparvovec (Hemgenix). 2023 Poster, AAHP, Little Rock.
- Desai V, **Johnson J.** An Evidence-based decision algorithm for drug coverage of IBS-C in adults. 2022. Presented at AAHP, Little Rock.
- McAdam-Marx C, Li C, **Johnson J.** Trends in insulin costs and utilization in commercially insured patients with diabetes: 2007-2014. Women in Research Poster Showcase. UAMS, 11/2019.
- Sanson S, **Johnson JT.** Development of evidence-based prior authorization criteria for onasemnogene abeparvovec-xioi (Zolgensma) as a medical benefit. Poster presented at AR Association of Health Systems Pharmacy (AAHP) Fall Seminar, Little Rock. 10/2019.
- **Johnson JT.** AR Pharmacists Association Annual Meeting. New Drugs Presentation. 6/7/2018. Rogers, AR.
- McPhee AL, **Johnson JT.** Plaque Psoriasis and Psoriatic Arthritis: Formulation of Evidence-based Prior Authorization Criteria. Poster presented at AR Association of Health Systems Pharmacy (AAHP) Fall Seminar, Little Rock. 10/2018.
- Walsh T, King J, **Johnson JT.** Cyclin Dependent Kinase Inhibitors for Advanced Hormone Receptor Positive, HER2-negative Breast Cancer. Presented at AAHP Fall Seminar, Little Rock. 10/2018.
- Quattlebaum SH, **Johnson JT.** Development of an Evidence-Based Prior Authorization Pathway for Ibalizumab (Trogarzo®). Poster at AAHP Fall Seminar, Little Rock. 10/2018. ****Received Honorable Mention****
- McAdam-Marx C, Li C, **Johnson JT.** Trends in Insulin Cost Share and Utilization in Commercially Insured Patients with Diabetes: 2007-2014. Poster presented at 2018 AMCP Nexus, Orlando, FL.
- Bemberg GB, **Johnson JT.** Accessibility of Information Concerning the Ramifications of Drug Coupons. Poster presented at AAHP Fall Seminar, Little Rock. 10/2014.
- Dayer LE, Merrell KS, **Johnson JT,** Hutchins LF. Treatment of metastatic melanoma with pazopanib: a report of 5 patient cases. Presented at AAHP Fall Seminar, Little Rock, AR, 10/2013.
- Brazeal J, **Johnson JT,** Neill KK. Development of an Evidence-based Prior Authorization Pathway for Colony-Stimulating Factors. Presented at AAHP Fall Seminar, Hot Springs, AR, 10/2012.
- **Johnson JT.** "Roflumilast". AR Medicaid Drug Utilization Review Board. Oct. 19, 2011.
- **Johnson JT.** "Newer Diabetes Drugs". Arkansas State Employees Drug Utilization & Evaluation Committee. 2/8/2011.

LOCAL ("COP" is College of Pharmacy.)

- **Johnson JT.** Managed Care Pharmacy. Noon workshop for implementing a student chapter of the Academy of Managed Care Pharmacy. 10/2019.
- **Johnson JT.** Managed Care Pharmacy-What is it? P1 Career Orientation. 2019, 2020.
- **Johnson JT.** Working with Clerkship Students. Mentoring New COP Faculty. 2018.
- GB Bemberg, **Johnson JT.** Pharmacy Benefit Experience. Stephens Insurance. Little Rock, AR, 2/21/18.
- **Johnson JT.** Anticoagulants-The Old and the New. 12/4/11. ACPE No. 0004-0000-11-061-L01-P.

EDITORIAL REVIEW since 2010

- **2020-present.** American Journal of Managed Care, Reviewer
- 2016 Pharmacotherapy Preparatory Review and Recertification Course, Study Designs chapter, Dec 2015.
- Textbook Chapter 10: Venous Thromboembolism. Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, eds. Pharmacotherapy Principles & Practice, 3rd edition, 2013.
- Textbook Chapter: Ch. 7 Venous Thromboembolism. Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, eds. Pharmacotherapy Principles & Practice, 2nd edition, 2010.
- ASHP PharmPrep Reviewer. Anemia Chapter. September 2010.

RESEARCH INVOLVEMENT since 2010

- Co-investigator; Evaluation of the Arkansas Medicaid Antibiotic Prescribing Program. PEW and Arkansas Department of Health. PI: William Golden, \$140,000 subcontract 7/1/21-6/30/22.
- Co-Investigator; Pilot Evaluation of an Audience Response System in a Pharmacist Continuing Education Meeting. Vanderbush R, **Johnson JT**, Hutchison L, West DS., 8/05.
- Study Coordinator and Sub-Investigator; A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization (EXCLAIM), \$113,500 from Aventis, UAMS, Little Rock, Arkansas, Rob Lavender, M.D., **Jill Johnson, Pharm.D.** 8/05.
- Study Coordinator; Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H376/95 Compared with Dose-Adjusted Warfarin (Coumadin®) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V), \$46,000 from Astra-Zeneca. UAMS, Little Rock, Arkansas, Eugene Smith, M.D., **Jill Johnson, Pharm.D.**
- A Retrospective Chart Review to compare anticoagulated atrial fibrillation patients in a private clinic vs. a university clinic's anticoagulation monitoring service. UAMS, Little Rock, Arkansas
- Improvement of Students' Assessment of Faculty in a Team-Taught Course, Teaching Scholars Formal Proposal. UAMS College of Pharmacy. Fall 1999-Spring 2000
- Study Coordinator; Challenge Study: A Multi-Center, Open-Label Study of Atorvastatin 10mg or 80mg or Simvastatin 20mg or 80mg in the Treatment of Patients with Hypercholesterolemia, \$69,000 from Parke-Davis. UAMS, Little Rock, Arkansas, 1998-1999
- Residency Project: An Open-Label Study of Fluvastatin in the Treatment of Patients with Hypercholesterolemia in Clinical Practice Settings, \$7200. Veterans Affairs Medical Center, Little Rock, Arkansas, 1993-1994

SERVICE since 2010

NATIONAL (current in BOLD)

- **Institute for Clinical and Economic Review Midwest Comparative Effectiveness Public Advisory Council (ICER Midwest CEPAC), 2016-2018, 2018-present, Chair 1/2024-12/2026.**
- National Association of Boards of Pharmacy (NABP) Naplex Item Writing Committee Member, 2017

STATE/REGIONAL (current in BOLD)

- **Arkansas State Employees' Benefits Consultant, Jan 2004 to Present**
- **Arkansas State Employees' Delivery Coordination Working Group, a subcommittee to the Drug Use and Evaluation Committee, 2013-present**
- Arkansas Medicaid Drug Utilization Review Board, Feb 2003 to Dec 2004, Jan 2007 to June 2023
- Pharmacy Advisory Committee Member, (large insurer in AR and beyond), 2016-2018
- Arkansas State Medicaid Drug Review Committee for the Arkansas Medicaid Evidence-based Prescription Drug Program, Nov 2004-May 2005, June 2005-Nov 2005, May 2006-Nov 2006, Jan 2010-June 2016
- Pharmacy & Therapeutics Voting Member, (large insurer in AR and beyond), 2014
- Arkansas Department of Health (ADH) Viral Hepatitis Epidemiologic Profile Stakeholder, April 2014

UNIVERSITY (current in BOLD)

- **UAMS High Cost Drugs Value Analysis Executive Committee, 2025 to present, non-voting member**
- **University Hospital Pharmacy and Therapeutics Committee, Voting Member, 1999 to present**
 - **Subcommittee on Targeted High-Cost Drugs, 2021-present, Chair 2024-present**
 - Subcommittee on Formulary Limits, 2010
 - Subcommittee on Statin Therapeutic Interchange 5/2006
- **University of Arkansas System Pharmacy Advisory Committee, 2004 to present**
 - RFP Team for PBM selection 2009
 - RFP Team for Pharmacy Consultant selection 2008
 - RFP Team for PBM selection 2006
- Faculty Life Cycle Committee, 2014

COLLEGE (current in BOLD)

- **Evidence-based Prescription Drug Program (EBRx) Pharmacy & Therapeutics Committee, Chair 2012-present**
- **Chancellor's (Faculty) Appeal Board, 2020-present**
- **Scholastic Standing Committee 2022-2026**
- **Search Committee, Chair. 2024-2025. Internal Medicine position. Family Medicine position.**
- UAMS COP Grievance Committee, 2024
- Exam Integrity Ad Hoc Committee, 2024
- Promotion and Tenure Committee Member: 2022-2023 (Alternate), 2019-2021, 2016-2018 (Chair 2017), 2014-2016 (Chair 2015, 2016), 2012-2014, 2010-2012, 2007-2008 Alternate, 2005-2007, 2002-2004
- Promotion & Tenure Ad Hoc Committee to Revise the P&T Document (Chair) 2017-2018, document approved
- Residency Review Committee, Member, Ad Hoc Committee in Pharmacy Practice, 2014-2016, 2016-2018
- Special Accommodations Committee, 2016
- Search Committee for Division Head, Pharmaceutical Evaluation & Policy (PEP), 2016
- MICU Candidate Search Committee, Chair 2014
- COP *ad hoc* Special Test Taking Accommodations Committee, 2007-2010